Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
The treatment of gastroesophageal adenocarcinoma (GEA) has undergone significant transformation as novel targeted and immunotherapies have been developed. In particular, multiple treatment approaches are now available for the management of HER2-positive disease across the treatment continuum for metastatic disease, with new therapeutic options poised to join the therapeutic arsenal.
This podcast summarizes recent advances in the management of advanced, HER2-positive GEA, with a particular focus on emerging treatment options, biomarker testing and principles for managing adverse events, led by Rohit Gosain, MD; and Rahul Gosain, MD.
Target Audience
This educational activity is directed toward US and Global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA and BTC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Understand the unique mechanisms of new and novel treatment approaches, including their implications for overcoming tumor heterogeneity and resistance
- Analyze pivotal trials and discuss how novel HER2-targeted therapies improve outcomes, address resistance mechanisms, and shape future strategies for HER2- positive GEA
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here